Boston Scientific Corporation (BSX) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Boston Scientific financial statements at a glance

Boston Scientific reported revenue of $20.07 billion for fiscal year 2025 (ended December 31, 2025), up 19.9% from fiscal year 2024. Net income was $2.90 billion, a net margin of 14.4%.

At the end of fiscal year 2025 it had total assets of $43.67 billion, total liabilities of $19.44 billion and shareholders' equity of $24.23 billion, with total debt of $11.44 billion.

Its operations brought in $4.53 billion of cash.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

BSX logo

Boston Scientific Corporation

BSXUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Revenue
20.07B
Prev Year: 16.75B
YoY: +19.9%
Total Revenue
-
Cost of Revenue
6.22B
Prev Year: 5.24B
YoY: +18.8%
Gross Profit
13.85B
Prev Year: 11.51B
YoY: +20.4%
SG&A Expenses
6.89B
Prev Year: 5.98B
YoY: +15.1%
Operating Expense
-
R&D Expense
2.05B
Prev Year: 1.61B
YoY: +27.1%
Depreciation/Amortization
897.00M
Prev Year: 856.00M
YoY: +4.8%
Net Non Operating Interest Income Expense
-
Other Operating Expenses, Total
17.00M
Prev Year: -3.00M
YoY: +666.7%
Other Income Expense
-
Operating Expenses
16.46B
Prev Year: 14.14B
YoY: +16.4%
Pre-tax Income
-
Operating Income
3.61B
Prev Year: 2.60B
YoY: +38.8%
Interest Inc.(Exp.),Net-Non-Op., Total
-193.00M
Prev Year: -293.00M
YoY: +34.1%
Net Income Common Stockholders
-
Other, Net
-35.00M
Prev Year: -28.00M
YoY: -25.0%
Diluted NI Available to Com Stockholders
-
Net Income Before Taxes
3.38B
Prev Year: 2.28B
YoY: +48.3%
Basic EPS
-
Provision for Income Taxes
493.00M
Prev Year: 436.00M
YoY: +13.1%
Diluted EPS
-
Net Income After Taxes
2.89B
Prev Year: 1.85B
YoY: +56.7%
Weighted Average Shares (basic)
-
Net Income Before Extra. Items
2.90B
Prev Year: 1.85B
YoY: +56.3%
Weighted Average Shares (diluted)
-
Net Income
2.90B
Prev Year: 1.85B
YoY: +56.3%
Total Operating Income as Reported
-
Income Available to Com Excl ExtraOrd
2.90B
Prev Year: 1.85B
YoY: +56.4%
Total Adjustments to Net Income
-
Prev Year: -1.00M
Total Expenses
-
Income Available to Com Incl ExtraOrd
2.90B
Prev Year: 1.85B
YoY: +56.4%
Net Income from Continuing and Discontinued Operation
-
Diluted Net Income
2.90B
Prev Year: 1.85B
YoY: +56.4%
Normalized Income
-
Diluted Weighted Average Shares
1.49B
Prev Year: 1.49B
YoY: +0.6%
Interest Expense
-
Diluted EPS Excluding ExtraOrd Items
1.939
Prev Year: 1.247
YoY: +55.5%
Net Interest Income
-
Diluted Normalized EPS
2.634
Prev Year: 2.011
YoY: +31.0%
EBIT
-
Unusual Expense (Income)
387.00M
Prev Year: 454.00M
YoY: -14.8%
EBITDA
-
Minority Interest
6.00M
Prev Year: 8.00M
YoY: -25.0%
Reconciled Cost of Revenue
-
Values in USD

Boston Scientific key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$20.1B$16.7B$14.2B$12.7B$11.9B
Gross profit$13.9B$11.5B$9.9B$8.8B$8.2B
Operating income$3.6B$2.6B$2.5B$1.5B$1.8B
Net income$2.9B$1.9B$1.6B$698.0M$985.0M
Diluted EPS––––$0.69
Total assets$43.7B$39.4B$35.1B$32.5B$32.2B
Total liabilities$19.4B$17.6B$15.9B$14.9B$15.6B
Shareholders' equity$24.2B$21.8B$19.3B$17.6B$16.6B
Cash––––$1.9B
Total debt$11.4B$10.7B$9.1B$8.9B$9.5B
Operating cash flow$4.5B$3.4B$2.5B$1.5B$1.9B
Capital spending––––$554.0M
Free cash flow––––$1.3B

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2020.

Questions and answers

What was Boston Scientific's revenue in fiscal year 2025?

$20.07 billion, up 19.9% from $16.75 billion in fiscal year 2024.

How much profit does Boston Scientific make?

Boston Scientific reported net income of $2.90 billion for fiscal year 2025 (14.4% of revenue); operating income was $3.61 billion.

How much cash and debt does Boston Scientific have?

At the end of fiscal year 2025: total debt of $11.44 billion.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube